The predictive value of neuroendocrine markers and p53 for response to chemotherapy and survival in patients with advanced non-small cell lung cancer

Lung Cancer

Volumn 36, Issue 2, 2002, Pages 159-165

  Gajra, Ajeet ^a   Tatum, Arthur H ^a   Newman, Nancy ^a   Gamble, Gary P ^b   Lichtenstein, Sonja ^c   Rooney, Michele T ^d   Graziano, Stephen L ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c IOWA METHODIST MEDICAL CENTER   (United States)

^d WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Chemotherapy response; Neuroendocrine expression; Non small cell lung cancer; p53; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; BIOCHEMICAL MARKER; CARBOPLATIN; CD57 ANTIGEN; CHROMOGRANIN A; CISPLATIN; NEURON SPECIFIC ENOLASE; PLATINUM DERIVATIVE; PROTEIN P53; SYNAPTOPHYSIN;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; ARTICLE; CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHROMOGRANIN A; CHROMOGRANINS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NERVE TISSUE PROTEINS; PHOSPHOPYRUVATE HYDRATASE; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; SYNAPTOPHYSIN; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036213519     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(01)00463-9     Document Type: Article

References (27)

1. Cancer statistics, 2001
2. Lung cancer biology
3. The pathology of lung cancer-changing concepts and newer diagnostic techniques
4. Histochemical studies of dense core granulated tumors of the lung
5. Preliminary report of a prospective trial of neuroendocrine marker analysis and in vitro drug sensitivity testing in patients with non-small cell lung cancer
6. The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small cell lung cancer
7. Prognostic impact of histologic demonstration of chromogranin A and neuron specific enolase in pulmonary adenocarcinoma
8. The impact of neuroendocrine (NE) and epithelial (EPI) differentiation on response and survival in lung cancer: the ECOG experience
9. Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer
10. Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated non-small cell lung carcinoma
11. Non-small cell lung cancer: clinical value of new biologic predictors
12. p53 and chemosensitivity
13. Induction of nuclear accumulation of tumor-suppressor protein p53 by DNA-damaging agents
14. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
15. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus mediated transfer of wild type p53 gene
16. The utility of p53 immunostaining of transbronchial specimens of lung cancer: p53 over-expression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer
17. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer
18. Single-agent paclitaxel by 3-h infusion in the treatment of non-small cell lung cancer: links between p53 and K-ras and gene status and chemosensitivity
19. Apoptotic death of tumor cells correlates with chemosensitivity independent of p53 and bcl-2
20. p53 mutations do not predict response to paclitaxel/radiation for non-small cell lung carcinoma
21. The prognostic significance of neuroendocrine markers and carcinoembryonic antigen in patients with resected stage I and II non-small cell lung cancer
22. Prognostic markers in resected stage I and II non-small cell cancer: an analysis of 260 patients with 5 year follow-up
23. Analysis of neuroendocrine markers, HER2 and CEA before and after chemotherapy in patients with stage IIIA non-small cell lung cancer: a cancer and leukemia Group B study
24. Clinical characterization of non small cell lung tumors showing neuroendocrine differentiation features
25. p53 nuclear immunostaining and gene mutations in non-small cell lung cancer and their effects on patient survival
26. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis